Stock Screener App

Frei -

Installieren

7.13

0.56% -0.04

after-market

Handel nachbörslich: 7.13

Entrada Therapeutics Inc (TRDA)

Überblick Nachrichten Preisverlauf Financials Forum Prognose

Entrada Therapeutics Inc Aktie (TRDA) Neueste Nachrichten

MPM BIOVENTURES 2018, L.P. Disposes 86,482 Shares of Entrada Therapeutics Between September 1-3, 2026 - Kalkine Media

Entrada Therapeutics' R&D President Sethuraman Natarajan Forfeits 2,079 Shares at $7.14 Each on September 2, 2026 - Kalkine Media

Entrada Therapeutics CFO Wentworth Kory James Forfeits 1,733 Shares at $7.14 Each (NASDAQ: TRDA) - Kalkine Media

TRDAEntrada Therapeutics Inc Revenue Breakdown - Finviz

Mpm Bioventures, 10% owner, sells $617k in Entrada Therapeutics By Investing.com - Investing.com Nigeria

Mpm Bioventures 2018 sells $617k Entrada Therapeutics shares By Investing.com - Investing.com Nigeria

Mpm Bioventures, 10% owner, sells $617k in Entrada Therapeutics - Investing.com

Institutional holder sells Entrada (NASDAQ: TRDA) shares over three days - Stock Titan

MPM funds sell Entrada (TRDA) shares without 10b5-1 plan - Stock Titan

Entrada Therapeutics (TRDA) CEO sale is tax-driven, still owns 517,290 shares - Stock Titan

Automatic tax sale trims Entrada Therapeutics (TRDA) CFO stake - Stock Titan

Automatic tax sale trims Entrada Therapeutics (TRDA) insider stake - Stock Titan

Automatic tax sale trims Entrada Therapeutics (TRDA) COO holdings - Stock Titan

Oppenheimer Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Maintains Target Price $23 - Moomoo

Liquidity Mapping Around (TRDA) Price Events - Stock Traders Daily

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - tradingview.com

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Moomoo

Mpm Bioventures 2018 sells $615,777 in Entrada Therapeutics stock By Investing.com - Investing.com Nigeria

Mpm Bioventures 2014 L.P. sells $615,777 of Entrada Therapeutics stock By Investing.com - Investing.com South Africa

Mpm Bioventures 2014 L.P. sells $615,777 of Entrada Therapeutics stock - Investing.com

Entrada Therapeutics (NASDAQ: TRDA) insider sells near $7 a share - Stock Titan

Entrada Therapeutics (TRDA) backer MPM funds sell 86,914 shares around $7 - Stock Titan

We Think Entrada Therapeutics (NASDAQ:TRDA) Needs To Drive Business Growth Carefully - Sahm

Mpm Bioventures 2018 sells $461,545 of Entrada Therapeutics stock By Investing.com - Investing.com Nigeria

Mpm Bioventures sells $461,545 in Entrada Therapeutics stock By Investing.com - Investing.com Australia

Entrada Therapeutics (TRDA) 10% owner sells shares outside a 10b5-1 plan - Stock Titan

Analysts Offer Insights on NA Companies: Rapport Therapeutics, Inc. (RAPP) and SpaceX (SPCX) - The Globe and Mail

Entrada (TRDA) Results Breakdown: Reported EPS Tops Expectations at the Close; Investor Response: Shares Move 2.31% Lower at the CloseShare Repurchase Impact - vinanet.vn

Entrada (TRDA) Earnings Update: Profit Per Share Surpasses Its Benchmark on the Day; Share Move: Shares Move Higher 7.02%Analyst Earnings Estimate - vinanet.vn

Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Celcuity (CELC) and Parabilis Medicines, Inc. (PBLS) - The Globe and Mail

(TRDA) Movement as an Input in Quant Signal Sets - Stock Traders Daily

Entrada Therapeutics Inc (TRDA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

HC Wainwright Analysts Lower Earnings Estimates for TRDA - marketbeat.com

Roth MKM Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Raises Target Price to $11 - Moomoo

Entrada Therapeutics director Kush Parmar sells $1.08 million in shares By Investing.com - Investing.com India

Major Insider Moves Shake Up Entrada Therapeutics Inc. Stock - TipRanks

Entrada Therapeutics director Kush Parmar sells $1.08 million in shares - Investing.com India

5am Ventures V, L.P. sells $431,829 of Entrada Therapeutics stock By Investing.com - Investing.com South Africa

5am Ventures V, L.P. sells $431,829 of Entrada Therapeutics stock - Investing.com

5AM Ventures V reports Entrada Therapeutics share disposal worth $431,620 - Bitget

Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $358,371.45 in Stock - MarketBeat

Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Director Sells $358,371.45 in Stock - MarketBeat

Entrada Therapeutics (TRDA): 5AM Ventures-linked funds sell 62,811 shares, retain over 1.09M - Stock Titan

Entrada Therapeutics Inc (TRDA) Stock News Today - TradingKey

Analysts’ Top Healthcare Picks: Insulet (PODD), Entrada Therapeutics Inc (TRDA) - The Globe and Mail

Entrada Therapeutics (NASDAQ:TRDA) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat

Entrada Therapeutics Releases Q2 2026 Financial Results - AlphaStreet

Entrada Therapeutics Submits Q2 2026 10-Q Report to SEC - Kalkine Media

Entrada Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Entrada Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView

Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance

Entrada Therapeutics, Inc. 2026: Revenue $898K, EPS ($1.01) — 10-Q Summary - TradingView

Entrada Therapeutics Reports Second Quarter 2026 Financial Results - The Manila Times

Entrada Therapeutics reports Q2 2026 results: $223.0M cash; Q2 net loss $42.8M - TradingView

Entrada Therapeutics (Nasdaq: TRDA) reports Q2 2026 results and sets DMD, DM1 data timeline - Stock Titan

Entrada Therapeutics director Kush Parmar sells $807,027 in shares By Investing.com - Investing.com India

5am Ventures V sells $807,027 of Entrada Therapeutics stock By Investing.com - Investing.com India

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat

5am Ventures V sells $807,027 of Entrada Therapeutics stock - Investing.com

Entrada Therapeutics director Kush Parmar sells $807,027 in shares - Investing.com

Ventures L.P. 5Am Sells 114,756 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock - marketbeat.com

BNTX

$103.76

0.86%

INSM

$126.29

0.31%

RPRX

$63.96

0.13%

ALNY

$266.11

0.61%

ONC

$358.26

1.22%

RVMD

$210.02

0.40%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters